QuidelOrtho
QDEL
#3663
Rank
NZ$5.03 B
Marketcap
$74.88
Share price
-1.85%
Change (1 day)
-34.04%
Change (1 year)
Quidel is an American manufacturer of diagnostics testings that can be used to diagnose infectious diseases as well as cardiovascular and metabolic diseases.

P/E ratio for QuidelOrtho (QDEL)

P/E ratio as of December 2024 (TTM): 215

According to QuidelOrtho's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 215.15. At the end of 2022 the company had a P/E ratio of 6.81.

P/E ratio history for QuidelOrtho from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
20226.81-15.25%
20218.04-13.99%
20209.34-77.84%
201942.270.96%
201824.7-113.08%
2017-188278.36%
2016-49.8-60.05%
2015-125-13.76%
2014-145-202.98%
201314012.81%
201212497.44%
201163.0-274.51%
2010-36.1-390.99%
200912.4-43.96%
200822.2-49.94%
200744.2117.68%
200620.3-154.79%
2005-37.146.08%
2004-25.4-258.01%
200316.1-76.77%
200269.2-91%
2001769

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
35.0-83.72%๐Ÿ‡บ๐Ÿ‡ธ USA
40.7-81.10%๐Ÿ‡บ๐Ÿ‡ธ USA
34.5-83.98%๐Ÿ‡บ๐Ÿ‡ธ USA
6.67-96.90%๐Ÿ‡บ๐Ÿ‡ธ USA
29.1-86.47%๐Ÿ‡บ๐Ÿ‡ธ USA
15.0-93.04%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.